Pancreatic Cancer Research

ResearcherThe University of Texas at San Antonio Health Science CenterActive in the last 2 years

Lei Zheng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4788-597X; OpenAlex author ID A5059709311. Sources: ClinicalTrials.gov.

Their work

Papers
20 (first author 1, last author 3)
Trials
3 (principal investigator on 3)
Grants
0
Labs led
1
Collaborators
83
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: 2 papers · 2016: none · 2017: none · 2018: 1 paper · 2019: 2 papers, 1 trial · 2020: 2 papers · 2021: none · 2022: 2 papers · 2023: 2 papers, 1 trial · 2024: 4 papers · 2025: 4 papers · 2026: 1 trial

Papers 20

  1. Phase 1 Study of Adjuvant Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor-Transduced Pancreatic Tumor Cell Vaccine, Low-Dose Cyclophosphamide, and … Co-author DOI 10.1016/j.ijrobp.2024.10.039↗
  2. Clinical outcomes and molecular characteristics of lung-only and liver-only metastatic pancreatic cancer: results from a real-world evidence database. Co-author DOI 10.1093/oncolo/oyaf007↗
  3. Homologous recombination-DNA damage response defects increase TMB and neoantigen load, but not effector T cell density and clonal diversity in pancreatic cance… Last author DOI 10.1186/s40164-025-00673-0↗
  4. EphA2-targeted alpha-particle theranostics for enhancing PDAC treatment. Co-author DOI 10.7150/thno.106948↗
  5. Clinical outcomes of liposomal irinotecan in patients with advanced pancreatic cancer previously treated with conventional irinotecan: A meta-analysis of real-… Co-author DOI 10.1002/cncr.35479↗
  6. Targeting heterogeneous tumor microenvironments in pancreatic cancer mouse models of metastasis by TGF-β depletion. Last author DOI 10.1172/jci.insight.182766↗
  7. Consensus, debate, and prospective on pancreatic cancer treatments. Last author DOI 10.1186/s13045-024-01613-x↗
  8. Variation in outcomes and practice patterns among patients with localized pancreatic cancer: the impact of the pancreatic cancer multidisciplinary clinic. Co-author DOI 10.3389/fonc.2024.1427775↗
  9. Single-cell RNA-seq reveals characteristics in tumor microenvironment of PDAC with MSI-H following neoadjuvant chemotherapy with anti-PD-1 therapy. Co-author DOI 10.1016/j.canlet.2023.216421↗
  10. Persistent Circulating Tumor Cells at 1 Year After Oncologic Resection Predict Late Recurrence in Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000005708↗
  11. Risk of Pancreatic Cancer in the Long-Term Prospective Follow-Up of Familial Pancreatic Cancer Kindreds. Co-author DOI 10.1093/jnci/djac167↗
  12. Gemcitabine and XCT790, an ERRα inverse agonist, display a synergistic anticancer effect in pancreatic cancer. Co-author DOI 10.7150/ijms.68404↗
  13. Association of Germline Variants in Human DNA Damage Repair Genes and Response to Adjuvant Chemotherapy in Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.jamcollsurg.2020.06.019↗
  14. An exploratory study of metformin with or without rapamycin as maintenance therapy after induction chemotherapy in patients with metastatic pancreatic adenocar… Co-author DOI 10.18632/oncotarget.27586↗
  15. Precision medicine in pancreatic cancer: treating every patient as an exception. First author DOI 10.1016/s2468-1253(19)30175-x↗
  16. The Significance of Ascites in Patients With Pancreatic Ductal Adenocarcinoma: A Case-Control Study. Co-author DOI 10.1097/mpa.0000000000001262↗
  17. Diagnostic intervals and pancreatic ductal adenocarcinoma (PDAC) resectability: a single-center retrospective analysis. Co-author DOI 10.21037/apc.2018.02.01↗
  18. Which patients with resectable pancreatic cancer truly benefit from oncological resection: is it destiny or biology? Co-author DOI 10.1080/15384047.2014.1002699↗
  19. The crown jewelry of the surgeries for pancreatic cancer. Co-author DOI 10.3978/j.issn.1000-9604.2015.06.10↗
  20. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. Co-author DOI 10.1097/cji.0b013e31829fb7a2↗

Trials 3

  1. Resection/Synchronous Pulmonary or Hepatic Oligometastatic Pancreatic Ductal Adenocarcinoma Principal investigator NCT07340151↗
  2. A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer Principal investigator NCT05604560↗
  3. Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma Principal investigator NCT03727880↗

Closest collaborators

The 25 strongest of 83 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Daniel A. Laheru · 8 shared papers, 2013–2025 · strength 0.97
  2. Amol Kumar Narang · 5 shared papers, 2019–2025 · strength 0.93
  3. Jing He · 4 shared papers, 2023–2025 · strength 0.91
  4. Dung Thi Le · 6 shared papers, 2013–2025 · strength 0.72
  5. Michael Jon Pishvaian · 3 shared papers, 2024–2025 · strength 0.68
  6. Joseph M. Herman · 3 shared papers, 2019–2025 · strength 0.55
  7. Elizabeth M. Jaffee · 4 shared papers, 2013–2025 · strength 0.54
  8. Ana De Jesus‐Acosta · 4 shared papers, 2018–2024 · strength 0.49
  9. Amy Hacker‐Prietz · 2 shared papers, 2024–2025 · strength 0.46
  10. Christopher Lee Wolfgang · 4 shared papers, 2015–2023 · strength 0.45
  11. Christopher L. Wolfgang · 2 shared papers, 2024–2025 · strength 0.44
  12. Sophia Y. Chen · 2 shared papers, 2024–2025 · strength 0.41
  13. Nicholas Jason Roberts · 2 shared papers, 2022–2025 · strength 0.38
  14. Jin Peng He · 3 shared papers, 2018–2022 · strength 0.32
  15. Arsen Osipov · 1 shared trial, 2019 · strength 0.30
  16. William R. Burns · 2 shared papers, 2020–2024 · strength 0.29
  17. Richard A. Burkhart · 2 shared papers, 2020–2023 · strength 0.29
  18. Priya Pathak · 1 shared paper, 2024 · strength 0.26
  19. Michael Goggins · 2 shared papers, 2020–2022 · strength 0.25
  20. Amol Gupta · 1 shared paper, 2024 · strength 0.24
  21. Junke Wang · 1 shared paper, 2024 · strength 0.24
  22. Keyu Li · 1 shared paper, 2024 · strength 0.24
  23. Neeha Zaidi · 1 shared paper, 2024 · strength 0.24
  24. Mengyue Lei · 1 shared paper, 2025 · strength 0.24
  25. Eric R. Lutz · 2 shared papers, 2013–2025 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.